Long‐lasting allergic patch test reactions to dental metal allergens in a patient with palmoplantar pustulosis and pustulotic arthro‐osteitis

Kato, Maiko; Oiso, Naoki; Yanagihara, Shigeto; Kawada, Akira

doi:10.1111/1346-8138.15471

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long-lasting allergic PT reactions (LLAPTR) are positive PT reactions lasting more than two weeks. A 90-year-old dental patient had a positive PT on D2 and D4 for platinum (Pt), Pd, and indium (In), but for Au the test was negative until D45 [ 53 ].…”

Section: Diagnosticsmentioning

confidence: 99%

Metal Allergy: State-of-the-Art Mechanisms, Biomarkers, Hypersensitivity to Implants

Zemelka‐Wiącek¹

2022

JCM

View full text Add to dashboard Cite

Metal allergy is mainly an environmental disorder which can cause allergic contact dermatitis. Environmental metal exposures include jewelry, everyday metal items, mobile phones, leather, metal-rich food and implants, including stents or anchors. While consumer exposure is liable for the majority of metal hypersensitivity cases, the significance of occupational exposure to metals remains relevant. Although the most common metal allergens are nickel, chromium, and cobalt; however, lately, gold, palladium, titanium, and some others have also attracted attention. This review highlights advances in metal allergy mechanisms, biomarkers for potential patients’ stratification as well as biological treatments. The most recent evidence of human exposure to metal for risk assessment is discussed, as well as the relationship between the occurrence of metal hypersensitivity and implanted devices, including non-characteristic symptoms. The latest data on the diagnosis of metal hypersensitivity are also reported.

show abstract

Section: Diagnosticsmentioning

confidence: 99%

Metal Allergy: State-of-the-Art Mechanisms, Biomarkers, Hypersensitivity to Implants

Zemelka‐Wiącek¹

2022

JCM

View full text Add to dashboard Cite

show abstract

“…2 Smoking is one of the important inducing factor 2 in PPP, and tonsillar streptococcal 3 or dental infections 4 may exacerbate PPP. Other triggering factors, including dental metal allergies 5 and some drugs, especially anti-TNF agents 6 may induce or exacerbate PPP.…”

Section: Introductionmentioning

confidence: 99%

Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series

Xu¹,

Wang²,

Yang³

et al. 2023

IDR

View full text Add to dashboard Cite

Background: Palmoplantar pustulosis (PPP) is a common chronic and recurrent skin disease of the palms and soles with significant pain, mental distress, and functional disability. PPP is challenging to treat and usually requires prolonged management. Therapy resistance and frequent relapse discourages patients from follow-up. No unified standard and no published therapeutic guidelines have yet been defined on PPP treatment. In general, all therapeutic options known for autoimmune diseases, psoriasis in particular, have been tested in PPP. Tofacitinib, an oral JAK inhibitor, has been approved for the treatment of rheumatoid arthritis and shows promise in the treatment of moderate-to-severe plaque psoriasis. However, no clinical trials or case reports have been conducted to confirm the efficacy of tofacitinib in palmoplantar pustulosis. Methods: Six in total with 6 PPP patient, aged 42-58 years were recruited according to the inclusion and exclusion criteria. Patient characteristics, including triggering factors, concomitant diseases, and previous therapeutic drugs, were investigated. All patients experienced a lack of response to topical drugs and at least one systemic agent. During treatment, visits were scheduled at the start of treatment and at 2, 4, and 12 weeks, and efficacy was assessed using the PPP ASI and PPP PGA. Results: Our six patients showed an excellent response to tofacitinib as all patients did achieve at least 50% reduction and half of our patients with more than 80% reduction in PPPASI after 4 weeks treatment; at week 12, 5 (83.3%) patients had 80% reduction in PPPASI with no serious adverse events were reported. Conclusion:The JAK inhibitor tofacitinib is a promising treatment for refractory palmoplantar pustulosis that requires further clinical observation and research.

show abstract

Long‐lasting allergic patch test reactions to dental metal allergens in a patient with palmoplantar pustulosis and pustulotic arthro‐osteitis

Cited by 2 publications

References 5 publications

Metal Allergy: State-of-the-Art Mechanisms, Biomarkers, Hypersensitivity to Implants

Metal Allergy: State-of-the-Art Mechanisms, Biomarkers, Hypersensitivity to Implants

Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series

Contact Info

Product

Resources

About